Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Medical Therapy, Università di Pavia, Pavia, Italy; European Blood and Marrow Transplantation (EBMT) Cell Therapy & Immunobiology Working Party.
Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Crit Rev Oncol Hematol. 2021 Mar;159:103224. doi: 10.1016/j.critrevonc.2021.103224. Epub 2021 Jan 22.
Germ cell tumors (GCTs) represent the best and the only example of solid tumors curable in the large majority of patients. GCTs are one of the few malignancies for which specific biochemical markers have been identified: human chorionic gonadotropin (HCG) and alfa-fetoprotein (AFP). Due to their specificity and sensitivity they constitute formidable tools in the diagnosis and monitoring of treatment for GCTs. As a tumor mass marker, lactate dehydrogenase (LDH) is also considered. Tumor markers are expressed in 15-20% of seminoma and 60-80% of non-seminoma. With the aim to increase sensitivity and specificity, recent studies have proposed miRNAs as serum biomarkers. This review will focus on role of serum tumor markers in diagnosis, staging, prognosis, monitoring of response, and finally follow-up of GCTs.
生殖细胞肿瘤(GCTs)是大多数患者可治愈的实体肿瘤中最好的也是唯一的范例。GCTs 是少数几种已经确定了特定生化标志物的恶性肿瘤之一:人绒毛膜促性腺激素(hCG)和甲胎蛋白(AFP)。由于其特异性和敏感性,它们在 GCT 的诊断和治疗监测中构成了强大的工具。乳酸脱氢酶(LDH)也被认为是肿瘤标志物。肿瘤标志物在 15-20%的精原细胞瘤和 60-80%的非精原细胞瘤中表达。为了提高灵敏度和特异性,最近的研究提出了将 microRNA 作为血清生物标志物。这篇综述将重点介绍血清肿瘤标志物在 GCT 的诊断、分期、预后、治疗反应监测以及最终随访中的作用。